Introduction the initiation of therapy to pneumonitis was

Introduction drug induced pneumonitis.
Drug induced pneumonitis is a type of non infectious lung inflammatory disease categorized
by infiltration of interstitial and alveolar (Cui et al., 2017). Interstitial pneumonitis involves
the pleura, multiple structures of the respiratory system, airways, lung parenchyma,
mediastinum, pulmonary vasculature and the neuromuscular system (Yonemori et al., 2016).
This often exhibits as a dyspnea, dry cough, chest tightness, low grade fever, pain, tachypnea,
tachycardia, cyanosis, and fatigue. The most common form of drug induced lung injury is
drug-induced interstitial pneumonitis. Pneumonitis can cause permanent respiratory failure
which requires chronic oxygen therapy (Yonemori et al., 2016).
Pneumonitis is a side effect associated with several cancer treatments, including radiation
therapy and chemotherapy as well as newer targeted drugs and immunotherapies (Yonemori
et al., 2016).
Pembrolizumab is a monoclonal antibody which binds to the programmed cell death protein
1 (PD-1) receptor and targets programmed death-ligands 1 (PD-L1) found on T-cells and 2
(PD-L2), releasing PD-1 pathway-mediated inhibition of anti-tumor proliferation.(Pai?Scherf
et al., 2017). A severe adverse effect of Pembrolizumab is pneumonitis, which may cause
significant morbidity and mortality (Kwok, Yau, Chiu, Tse & Kwong., 2016). The median
time from the initiation of therapy to pneumonitis was 2 to 6 months, even though it could
occur after one to two doses of a PD-1/PD-L1 inhibitor (Li et al., 2017).
Mdm. Ken is currently admitted for shortness of breath for few weeks and she was noted to
be long standing dyspnea for few weeks after she was started on Pembrolizumab, Low
percutaneous arterial oxygen saturation, cough, fatigue, loss of appetite, loss of weight and
increasing requirement of oxygen therapy. The issue identified in this admission includes,
lower back pain. The purpose of this essay the author has no previous experience of